SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2003
OR
o TRANSITION REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number 0-22229
VITAL IMAGES, INC.
(Exact name of registrant as specified in its charter)
Minnesota |
|
42-1321776 |
|
(State or other jurisdiction
of |
|
(I.R.S. Employer Identification No.) |
|
|
|
|
|
3300 Fernbrook Lane N., Suite 200 |
|
|
|
Plymouth, Minnesota |
|
55447 |
|
(Address of principal |
|
(Zip Code) |
|
|
|
|
|
(763) 852-4100 |
||
|
(Registrant’s telephone number, including area code) |
||
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No o
Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes ý No o
On November 10, 2003, there were 11,116,357 shares of the Registrant’s common stock, par value $.01 per share, outstanding.
VITAL IMAGES, INC.
Form 10-Q
September 30, 2003
Table of Contents
2
VITAL IMAGES, INC.
AS OF SEPTEMBER 30, 2003 AND DECEMBER 31, 2002
|
|
|
September 30, |
|
December 31, |
|
||
|
|
|
(Unaudited) |
|
|
|
||
|
ASSETS |
|
|
|
|
|
||
|
Current assets: |
|
|
|
|
|
||
|
Cash and cash equivalents |
|
$ |
28,827,329 |
|
$ |
8,122,547 |
|
|
Marketable securities |
|
5,283,113 |
|
2,508,113 |
|
||
|
Accounts receivable, net of allowance for doubtful accounts of $273,000 and $240,000 as of September 30, 2003 and December 31, 2002, respectively |
|
6,342,151 |
|
4,971,079 |
|
||
|
Deferred income taxes |
|
290,000 |
|
— |
|
||
|
Prepaid expenses and other current assets |
|
929,728 |
|
498,692 |
|
||
|
Total current assets |
|
41,672,321 |
|
16,100,431 |
|
||
|
Property and equipment, net |
|
2,729,272 |
|
2,156,835 |
|
||
|
Deferred income taxes |
|
8,585,000 |
|
— |
|
||
|
Licensed technology, net |
|
480,000 |
|
570,000 |
|
||
|
|
|
|
|
|
|
||
|
TOTAL ASSETS |
|
$ |
53,466,593 |
|
$ |
18,827,266 |
|
|
|
|
|
|
|
|
||
|
LIABILITIES AND SHAREHOLDERS’ EQUITY |
|
|
|
|
|
||
|
Current liabilities: |
|
|
|
|
|
||
|
Accounts payable |
|
$ |
1,050,062 |
|
$ |
757,715 |
|
|
Accrued payroll |
|
1,816,785 |
|
1,486,654 |
|
||
|
Deferred revenue |
|
5,536,114 |
|
3,870,958 |
|
||
|
Accrued royalties |
|
733,017 |
|
546,593 |
|
||
|
Other current liabilities |
|
242,816 |
|
219,036 |
|
||
|
Total current liabilities |
|
9,378,794 |
|
6,880,956 |
|
||
|
Deferred revenue |
|
276,283 |
|
225,539 |
|
||
|
Total liabilities |
|
9,655,077 |
|
7,106,495 |
|
||
|
|
|
|
|
|
|
||
|
Shareholders’ equity: |
|
|
|
|
|
||
|
Preferred stock: $.01 par value; 5,000,000 shares authorized; none issued or outstanding as of September 30, 2003 and December 31, 2002 |
|
— |
|
— |
|
||
|
Common stock: $.01 par value; 20,000,000 shares authorized; 11,088,831 and 8,987,009 shares issued and outstanding as of September 30, 2003 and December 31, 2002, respectively |
|
110,888 |
|
89,870 |
|
||
|
Additional paid-in capital |
|
55,664,086 |
|
31,719,371 |
|
||
|
Accumulated other comprehensive income |
|
373 |
|
— |
|
||
|
Accumulated deficit |
|
(11,963,831 |
) |
(20,088,470 |
) |
||
|
Total shareholders’ equity |
|
43,811,516 |
|
11,720,771 |
|
||
|
|
|
|
|
|
|
||
|
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY |
|
$ |
53,466,593 |
|
$ |
18,827,266 |
|
(The accompanying notes are an integral part of the interim financial statements.)
3
VITAL IMAGES, INC.
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2003 AND 2002
|
|
|
For the
Three |
|
For the
Nine |
|
||||||||
|
|
|
2003 |
|
2002 |
|
2003 |
|
2002 |
|
||||
|
|
|
(Unaudited) |
|
(Unaudited) |
|
||||||||
|
Revenue: |
|
|
|
|
|
|
|
|
|
||||
|
License fees |
|
$ |
5,258,320 |
|
$ |
4,022,420 |
|
$ |
15,236,591 |
|
$ |
10,315,561 |
|
|
Maintenance and services |
|
1,638,147 |
|
836,482 |
|
4,688,809 |
|
2,678,388 |
|
||||
|
Hardware |
|
346,263 |
|
733,987 |
|
1,638,021 |
|
1,916,664 |
|
||||
|
Total revenue |
|
7,242,730 |
|
5,592,889 |
|
21,563,421 |
|
14,910,613 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Cost of revenue: |
|
|
|
|
|
|
|
|
|
||||
|
License fees |
|
604,634 |
|
337,388 |
|
1,506,585 |
|
881,210 |
|
||||
|
Maintenance and services |
|
276,984 |
|
208,379 |
|
952,061 |
|
900,636 |
|
||||
|
Hardware |
|
259,326 |
|
566,091 |
|
1,097,316 |
|
1,473,374 |
|
||||
|
Total cost of revenue |
|
1,140,944 |
|
1,111,858 |
|
3,555,962 |
|
3,255,220 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Gross margin |
|
6,101,786 |
|
4,481,031 |
|
18,007,459 |
|
11,655,393 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
||||
|
Sales and marketing |
|
2,929,746 |
|
2,200,682 |
|
8,737,252 |
|
5,893,358 |
|
||||
|
Research and development |
|
1,310,417 |
|
1,154,030 |
|
4,004,795 |
|
3,001,622 |
|
||||
|
General and administrative |
|
967,084 |
|
736,622 |
|
3,066,854 |
|
2,472,216 |
|
||||
|
Total operating expenses |
|
5,207,247 |
|
4,091,334 |
|
15,808,901 |
|
11,367,196 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Operating income |
|
894,539 |
|
389,697 |
|
2,198,558 |
|
288,197 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Interest income, net |
|
70,468 |
|
32,452 |
|
146,081 |
|
93,991 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Income before income taxes |
|
965,007 |
|
422,149 |
|
2,344,639 |
|
382,188 |
|
||||
|
Provision (benefit) for income taxes |
|
(5,840,000 |
) |
3,000 |
|
(5,780,000 |
) |
9,000 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Net income |
|
$ |
6,805,007 |
|
$ |
419,149 |
|
$ |
8,124,639 |
|
$ |
373,188 |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Net income per share – basic |
|
$ |
0.62 |
|
$ |
0.05 |
|
$ |
0.82 |
|
$ |
0.04 |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Net income per share – diluted |
|
$ |
0.53 |
|
$ |
0.04 |
|
$ |
0.70 |
|
$ |
0.04 |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Shares used in per share calculations: |
|
|
|
|
|
|
|
|
|
||||
|
Basic |
|
10,954,998 |
|
8,956,337 |
|
9,875,771 |
|
8,822,722 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Diluted |
|
12,767,022 |
|
9,623,682 |
|
11,572,949 |
|
9,809,445 |
|
||||
(The accompanying notes are an integral part of the interim financial statements.)
4
VITAL IMAGES, INC.
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2003 AND 2002
|
|
|
For the
Nine |
|
||||
|
|
|
2003 |
|
2002 |
|
||
|
|
|
(Unaudited) |
|
||||
|
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
|
|
|
||
|
Net income |
|
$ |
8,124,639 |
|
$ |
373,188 |
|
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
||
|
Depreciation and amortization |
|
882,227 |
|
643,871 |
|
||
|
Stock-based compensation |
|
123,911 |
|
7,300 |
|
||
|
Provision for uncollectible accounts receivable |
|
33,000 |
|
33,000 |
|
||
|
Deferred income tax benefit |
|
(5,885,000 |
) |
— |
|
||
|
Amortization of licensed technology |
|
90,000 |
|
90,000 |
|
||
|
Changes in operating assets and liabilities: |
|
|
|
|
|
||
|
Accounts receivable |
|
(1,404,072 |
) |
(2,179,417 |
) |
||
|
Prepaid expenses and other current assets |
|
(431,036 |
) |
(148,986 |
) |
||
|
Accounts payable |
|
292,347 |
|
73,771 |
|
||
|
Deferred revenue |
|
1,715,900 |
|
1,435,636 |
|
||
|
Accrued expenses and other liabilities |
|
540,335 |
|
115,599 |
|
||
|
Net cash provided by operating activities |
|
4,082,251 |
|
443,962 |
|
||
|
|
|
|
|
|
|
||
|
CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
|
|
|
||
|
Additions to property and equipment |
|
(1,454,664 |
) |
(1,034,785 |
) |
||
|
Additions to licensed technology |
|
— |
|
— |
|
||
|
Investments in marketable securities |
|
(6,203,277 |
) |
(5,932,219 |
) |
||
|
Maturities of marketable securities |
|
3,428,650 |
|
2,022,754 |
|
||
|
Net cash used in investing activities |
|
(4,229,291 |
) |
(4,944,250 |
) |
||
|
|
|
|
|
|
|
||
|
CASH FLOWS FROM FINANCING ACTIVITIES: |
|
|
|
|
|
||
|
Proceeds from sales of common stock under warrants |
|
210,759 |
|
1,719,123 |
|
||
|
Proceeds from sales of common stock under stock plans |
|
1,650,548 |
|
1,070,039 |
|
||
|
Net proceeds from private placement |
|
18,990,515 |
|
— |
|
||
|
Net cash provided by financing activities |
|
20,851,822 |
|
2,789,162 |
|
||
|
|
|
|
|
|
|
||
|
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS |
|
20,704,782 |
|
(1,711,126 |
) |
||
|
|
|
|
|
|
|
||
|
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD |
|
8,122,547 |
|
6,830,906 |
|
||
|
|
|
|
|
|
|
||
|
CASH AND CASH EQUIVALENTS, END OF PERIOD |
|
$ |
28,827,329 |
|
$ |
5,119,780 |
|
|
|
|
|
|
|
|
||
|
SUPPLEMENTAL CASH FLOW INFORMATION: |
|
|
|
|
|
||
|
Income taxes paid |
|
$ |
68,157 |
|
$ |
9,593 |
|
(The accompanying notes are an integral part of the interim financial statements.)
5
VITAL IMAGES, INC.
(Unaudited)
(1) BASIS OF PRESENTATION:
The accompanying unaudited financial statements of Vital Images, Inc. (“Vital Images” or the “Company”) have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and notes required by accounting principles generally accepted in the United States of America. In the opinion of management, these unaudited financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. Operating results for the nine months ended September 30, 2003 are not necessarily indicative of the results that may be expected for the year ending December 31, 2003. These financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2002.
A reclassification related to the amortization of technology licensed from a third party has been made in the third quarter of 2003 to the year-to-date 2003 and the 2002 financial statements to conform to the current financial statement presentation. For the first six months of 2003, $60,000 of amortization expense was reclassified from research and development expenses to license fees cost of revenue. For the three and nine months ended September 30, 2002, $30,000 and $90,000, respectively, of amortization expense was reclassified from research and development expenses to license fees cost of revenue.
(2) MAJOR CUSTOMERS AND GEOGRAPHIC DATA:
The following customers accounted for more than 10% of the Company’s total revenue for the periods indicated:
|
|
|
Significant |
|
Revenue |
|
Percentage
of |
|
|
|
Nine months ended September 30, 2003 |
|
Toshiba Medical Systems Corporation |
|
$ |
9,777,000 |
|
45 |
% |
|
|
|
|
|
|
|
|
|
|
|
Nine months ended September 30, 2002 |
|
Toshiba Medical Systems Corporation |
|
$ |
5,486,000 |
|
37 |
% |
The Company’s accounts receivable are generally concentrated with a small base of customers. As of September 30, 2003 and December 31, 2002, Toshiba Medical Systems Corporation accounted for 53% and 21% of accounts receivable, respectively.
Export revenue amounted to 12% and 8% of total revenue for the nine months ended September 30, 2003 and 2002, respectively. Substantially all of the Company’s export revenue is negotiated, invoiced and paid in U.S. dollars. Gross export revenue by geographic area is summarized as follows:
6
|
|
|
Nine
Months Ended |
|
||||
|
|
|
2003 |
|
2002 |
|
||
|
Europe |
|
$ |
1,825,000 |
|
$ |
652,000 |
|
|
Asia and Pacific Region |
|
525,000 |
|
457,000 |
|
||
|
Canada, Mexico and other foreign countries |
|
268,000 |
|
92,000 |
|
||
|
Totals |
|
$ |
2,618,000 |
|
$ |
1,201,000 |
|
(3) NET INCOME PER SHARE:
Net income per share - basic is computed using the weighted average common shares outstanding during the period. Net income per share – diluted is computed using the weighted average common shares outstanding and common share equivalents shares outstanding during the period. Common share equivalents are not included in the net income per share calculations if they are anti-dilutive. Common share equivalents consist of warrants and options. There were no anti-dilutive common share equivalents for the three months ended September 30, 2003. For the nine months ended September 30, 2003, 43,471 common share equivalents were excluded because they were anti-dilutive. For the three and nine months ended September 30, 2002, 911,076 and 73,496, respectively, of common share equivalents were excluded because they were anti-dilutive.
The computations for basic and diluted net income per share for each period are as follows:
|
|
|
For the
Three Months Ended |
|
For the
Nine Months Ended |
|
||||||||
|
|
|
2003 |
|
2002 |
|
2003 |
|
2002 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Numerator: |
|
|
|
|
|
|
|
|
|
||||
|
Net income |
|
$ |
6,805,007 |
|
$ |
419,149 |
|
$ |
8,124,639 |
|
$ |
373,188 |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Denominator: |
|
|
|
|
|
|
|
|
|
||||
|
Denominator for weighted average common shares outstanding – basic |
|
10,954,998 |
|
8,956,337 |
|
9,875,771 |
|
8,822,722 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Dilution associated with common stock warrants |
|
80,290 |
|
45,992 |
|
77,478 |
|
60,753 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Dilution associated with the company’s stock-based compensation plans |
|
1,731,734 |
|
621,353 |
|
1,619,700 |
|
925,970 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Denominator for weighted average common shares outstanding – diluted |
|
12,767,022 |
|
9,623,682 |
|
11,572,949 |
|
9,809,445 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Net income per share – basic |
|
$ |
0.62 |
|
$ |
0.05 |
|
$ |
0.82 |
|
$ |
0.04 |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Net income per share – diluted |
|
$ |
0.53 |
|
$ |
0.04 |
|
$ |
0.70 |
|
$ |
0.04 |
|
7
(4) COMPREHENSIVE INCOME:
The components of comprehensive income were as follows:
|
|
|
For the
Three Months Ended |
|
For the
Nine Months Ended |
|
||||||||
|
|
|
2003 |
|
2002 |
|
2003 |
|
2002 |
|
||||
|
Net income |
|
$ |
6,805,007 |
|
$ |
419,149 |
|
$ |
8,124,639 |
|
$ |
373,188 |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Other comprehensive gain (loss): |
|
|
|
|
|
|
|
|
|
||||
|
Net unrealized gain (loss) on available-for-sale investments |
|
(268 |
) |
— |
|
373 |
|
— |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Comprehensive income |
|
$ |
6,804,739 |
|
$ |
419,149 |
|
$ |
8,125,012 |
|
$ |
373,188 |
|
Accumulated other comprehensive gain at September 30, 2003 and December 31, 2002 was $373 and $0, respectively.
(5) STOCK-BASED COMPENSATION:
The Company has stock-based employee and director compensation plans, which the Company accounts for under the recognition and measurement principles of APB Opinion No. 25, Accounting for Stock Issued to Employees, and related Interpretations. No stock-based employee and director compensation cost is reflected in net income (loss), as all options granted under those plans had an exercise price equal to the market value of the underlying common stock on the date of grant. The following table illustrates the effect on net income (loss) and net income (loss) per share if the Company had applied the fair value recognition provisions of Statement of Financial Accounting Standard (SFAS) No. 123, Accounting for Stock-Based Compensation, to stock-based employee and director compensation.
8
|
|
|
For the
Three Months Ended |
|
For the Nine
Months Ended |
|
|||||||||
|
|
|
2003 |
|
2002 |
|
2003 |
|
2002 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|||||
|
Net income, as reported |
|
$ |
6,805,007 |
|
$ |
419,149 |
|
$ |
8,124,639 |
|
$ |
373,188 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deduct: Total stock-based employee compensation expense determined under fair value method for all awards, net of related tax effects |
|
(556,007 |
) |
(468,149 |
) |
(1,573,639 |
) |
(1,375,188 |
) |
|||||
|
|
|
|
|
|
|
|
|
|
|
|||||
|
Pro forma net income (loss) |
|
$ |
6,249,000 |
|
$ |
(49,000 |
) |
$ |
6,551,000 |
|
$ |
(1,002,000 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
Net income (loss) per share – basic |
As reported |
|
$ |
0.62 |
|
$ |
0.05 |
|
$ |
0.82 |
|
$ |
0.04 |
|
|
|
|
|
$ |
0.57 |
|
$ |
(0.01 |
) |
$ |
0.66 |
|
$ |
(0.11 |
) |
|
|
Pro forma |
|
|
|
|
|
|
|
|
|
||||
|
Net income (loss) per share – diluted |
As reported |
|
$ |
0.53 |
|
$ |
0.04 |
|
$ |
0.70 |
|
$ |
0.04 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Pro forma |
|
$ |
0.49 |
|
$ |
(0.01 |
) |
$ |
0.57 |
|
$ |
(0.11 |
) |
The pro forma effects on the net income for the nine months ended September 30, 2003 and 2002 may not be indicative of the future results for the full fiscal year due to continuing option activity and other factors.
(6) INCOME TAXES:
During the third quarter of 2003, the Company concluded that it is more likely than not that all of its net deferred tax assets will be realized and the Company reversed its valuation allowance for net deferred tax assets, which resulted in the recording of a net tax benefit for the three months and nine months ended September 30, 2003. The reversal of the deferred tax assets valuation allowance is based upon the Company’s historical operating performance and management’s expectation that the Company will generate sufficient taxable income of approximately $25 million in future periods to allow it to realize its deferred tax assets resulting from the tax benefits associated with its net operating loss carryforwards and a significant portion of its research and development tax credit carryforwards, as well as certain other tax benefits related to book and tax income timing differences. The Company reversed its valuation allowance for net deferred tax assets of approximately $6.4 million on September 30, 2003. Of the total $6.4 million valuation allowance reversal, approximately $5.9 million was recorded as a tax benefit in the statements of operations, and approximately $530,000 as an increase to additional paid-in capital, which represents the amount of deferred tax assets generated from the exercise of stock options prior to 2003. In addition, the Company recorded a $2.5 million increase in additional paid-in-capital related to the deferred tax asset generated by stock option exercises in the first nine months of 2003.
The following table summarizes the significant components of the Company’s tax-effected net deferred income taxes.
9
|
|
|
For the Nine |
|
For the Year |
|
||
|
Net operating loss carryforwards |
|
$ |
7,915,000 |
|
$ |
6,830,000 |
|
|
Research and development tax credit carryforwards |
|
978,000 |
|
995,000 |
|
||
|
Deferred compensation |
|
— |
|
230,000 |
|
||
|
Depreciation |
|
237,000 |
|
322,000 |
|
||
|
Other, net |
|
290,000 |
|
221,000 |
|
||
|
Net deferred income taxes before valuation allowance |
|
9,420,000 |
|
8,598,000 |
|
||
|
Less valuation allowance |
|
(545,000 |
) |
(8,598,000 |
) |
||
|
Net deferred income taxes |
|
$ |
8,875,000 |
|
$ |
— |
|
The Company expects to reverse approximately $400,000 of the remaining valuation allowance of $545,000 in the fourth quarter of 2003.
(7) PRIVATE PLACEMENT:
In June 2003, the Company completed a private placement of 1,500,000 shares of common stock at $13.50 per share for total gross proceeds of $20,250,000. After deducting placement fees and other offering costs of $1,259,000, the Company received net proceeds of $18,991,000. A registration statement covering the resale of these shares was declared effective on September 29, 2003 by the Securities and Exchange Commission.
(8) RECENT ACCOUNTING PRONOUNCEMENTS:
In December 2002, the FASB issued SFAS No. 148, “Accounting for Stock-Based Compensation – Transition and Disclosure – an amendment of SFAS No. 123.” This Statement amends SFAS 123, “Accounting for Stock-Based Compensation”, to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based compensation. In addition, SFAS 148 amends the disclosure requirements of SFAS 123 to require prominent disclosures in both annual and interim financial statements about the method of accounting for stock-based compensation and the effect of the method used on reported results. SFAS 148 is effective for fiscal years ending after December 15, 2002, and disclosure requirements are effective for interim periods beginning after December 15, 2002. The Company has provided the additional disclosures required by SFAS 148 in the first three quarters of 2003. The Company intends to continue to account for stock-based compensation using the intrinsic value method prescribed by APB Opinion No. 25 and related interpretations. Accordingly, the adoption of SFAS 148 did not impact the Company’s financial position or results of operations.
In November 2002, the FASB issued Interpretation No. 45, “Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others.” This interpretation elaborates on the disclosures required in financial statements concerning obligations under certain guarantees. It also clarifies the requirements related to the recognition of liabilities by a guarantor at the inception of certain guarantees. The disclosure requirements of this interpretation were effective for the Company on December 31, 2002 and, accordingly, are reflected in the Company’s financial statements. The recognition provisions of the interpretation are effective for the Company in 2003 and are applicable only to guarantees issued or modified after December 31, 2002. Adoption of this interpretation did not have an impact on the Company’s financial position or results of operations.
10
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Overview
Vital Images develops, markets and supports 3D medical imaging software for use primarily in disease screening, clinical diagnosis and therapy planning. The Company’s software applies proprietary computer graphics and image processing technologies to a wide variety of data supplied by computed tomography (“CT”) scanners and magnetic resonance (“MR”) imaging devices. Vital Images’ products allow clinicians to create both two- and three-dimensional views of human anatomy and to non-invasively navigate within these images to better visualize and understand internal structures and pathologies. The Company believes that its high-speed visualization technology and customized protocols cost-effectively bring 3D visualization and analysis into the routine, day-to-day practice of medicine. The Company, which operates in a single business segment, markets its products to healthcare providers and to manufacturers of diagnostic imaging systems through a direct sales force in the United States and independent distributors in international markets.
Critical Accounting Policies and Estimates
Management’s discussion and analysis of its financial position and results of operations are based upon the Company’s consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. The following represents those critical accounting policies and estimates where materially different amounts could be reported under different conditions or using different assumptions.
Allowance for doubtful accounts. The Company maintains an allowance for doubtful accounts that reflects the Company’s estimate of losses that may result from the uncollectibility of accounts receivable. The allowance for doubtful accounts is based on an analysis of individual accounts for which the Company has information indicating the customer may not be able to pay amounts owed to the Company. In these cases, based on the available facts and circumstances, the Company estimates the amount that will be collected from such customers. The Company also evaluates the collectibility of our accounts receivable in the aggregate based on factors such as the aging of receivable amounts, customer concentrations, historical experience, and current economic trends and conditions. The allowance for doubtful accounts is adjusted when additional information is received that impacts the amount reserved. If circumstances change, the Company’s estimates of the recoverability of accounts receivable could be reduced or increased by a material amount. Such a change in estimated recoverability would be accounted for in the period in which the facts that give rise to the change become known. As of September 30, 2003, the Company had an allowance for doubtful accounts of $273,000.
Deferred tax asset. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. During the third quarter of 2003, the Company concluded that it is more likely than not that all of its net deferred tax assets will be realized and the Company reversed its valuation allowance for net deferred tax assets, which resulted in the recording of a net tax benefit for the three months and nine months ended September 30, 2003. The reversal of the deferred tax assets valuation allowance is based upon the Company’s historical operating performance and management’s expectation that the Company will generate sufficient taxable income of approximately $25 million in future periods to allow it to realize its deferred tax assets resulting from the tax benefits associated with its net operating loss carryforwards and a significant
11
portion of its research and development tax credit carryforwards, as well as certain other tax benefits related to book and tax income timing differences. The Company reversed its valuation allowance for net deferred tax assets of approximately $6.4 million at September 30, 2003. Of the total $6.4 million valuation allowance reversal, approximately $5.9 million was recorded as a tax benefit in the statements of operations, and approximately $530,000 as an increase to additional paid-in capital, which represents the amount of deferred tax assets generated from the exercise of stock options prior to 2003. In addition, the Company recorded a $2.5 million increase in deferred tax assets and additional paid-in-capital related to the deferred tax asset generated by stock option exercises in the first nine months of 2003. The Company expects to reverse approximately $400,000 of the remaining valuation allowance of $545,000 in the fourth quarter of 2003. Should the Company determine that it would not be able to realize all or part of its net deferred tax asset in the future, an adjustment to record a valuation allowance to reduce the deferred tax assets would be charged to income in the period such a determination was made.
Long-Lived Assets. The Company periodically reviews the carrying amounts of property and equipment and intangible assets purchased in the normal course of business to determine whether current events or circumstances, as defined in Statement of Financial Accounting Standard No 144, “Accounting for the Impairment or Disposal of Long-Lived Assets,” warrant adjustments to such carrying amounts. In reviewing the carrying values of property and equipment and intangible assets purchased in the normal course of business, the Company considers, among other things, the future cash flows expected from the use of the asset. To the extent these estimated cash flows significantly change, an impairment would be identified.
Revenue Recognition. The Company licenses its software and sells products and services to end-users and also indirectly through OEMs and independent distributors. Terms offered by the Company do not differ based on whether the customer is an end-user, OEM or independent distributor. The Company offers terms that require payment within 30 to 90 days after product delivery. The Company does not offer rights of return, acceptance clauses or price protection to its customers.
License fees revenue is derived from the licensing of computer software. Hardware revenue is derived from the sale of system hardware, including peripheral equipment. Maintenance and service revenue is derived from hardware and software maintenance and from services consisting of installation, training and engineering services. The Company’s software licenses are always sold as part of an arrangement that includes a maintenance arrangement and often installation and training services. The Company generally sells hardware as part of a system sale, which includes a software license and often installation and training services. Occasionally, the Company sells hardware as part of a system upgrade or additional product sale. Engineering services consist of software modification or development services that are sold separately to OEMs.
The Company recognizes revenue in accordance with AICPA Statement of Position (“SOP”) 97-2, Software Revenue Recognition, as amended by SOP 98-4 and SOP 98-9, as well as Technical Practice Aids issued from time to time by the American Institute of Certified Public Accountants and Staff Accounting Bulletin (SAB) No. 101. The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when it has persuasive evidence of an arrangement, the product has been shipped or the services have been provided to the customer, the sales price is fixed or determinable and collectibility is probable.
The Company evaluates the credit worthiness of all customers. In circumstances where the Company does not have experience selling to a customer and lacks adequate credit information to conclude collection is probable, revenue is deferred until the arrangement fees are collected and all other revenue recognition criteria in the
12
arrangement have been met.
In addition to the aforementioned general policy, the following are the specific revenue recognition policies for services and multiple-element arrangements.
Software and Hardware
Revenue from license fees and hardware is recognized when shipment of the product has occurred, no significant Company obligations with regard to implementation remain and the Company’s services are not considered essential to the functionality of other elements of the arrangement. See also “Multiple Element Arrangements” below for further information.
Services
Revenue from maintenance arrangements is deferred and recognized ratably over the term of the maintenance arrangements.
Revenue from training and installation services is recognized as the services are provided to customers.
Revenue from engineering services, where the Company is performing significant customization or modification of software, is recognized using contract accounting on a percentage-of-completion basis. The Company records revenue by reference to actual hours incurred to date and the estimated hours remaining to complete the services.
Multiple-Element Arrangements
The Company enters into arrangements with customers that include a combination of software products, system hardware, specified upgrades, maintenance or installation and training services. For such arrangements, the Company recognizes revenue using the residual value method. The Company allocates the total arrangement fee among each deliverable element of the arrangement based on the relative fair value of each of the deliverable elements determined based on vendor-specific objective evidence. The fair value of maintenance services is based upon the renewal rate for continued service arrangements. The fair value of installation and training services is established based upon separate pricing for the services. In software arrangements for which the Company does not have vendor-specific objective evidence of fair value for all elements, revenue is deferred until the earlier of when vendor-specific objective evidence is determined for the undelivered elements (residual method) or when all elements have been delivered.
Reclassification
A reclassification related to the amortization of technology licensed from a third party has been made in the third quarter of 2003 to the year-to-date 2003 and the 2002 financial statements to conform to the current financial statement presentation. For the first six months of 2003, $60,000 of amortization expense was reclassified from research and development expenses to license fees cost of revenue. For the three and nine months ended September 30, 2002, $30,000 and $90,000, respectively, of amortization expense was reclassified from research and development expenses to license fees cost of revenue.
Revenue was $7,243,000 for the three months ended September 30, 2003, compared with $5,593,000 for the three months ended September 30, 2002, a 29% increase. For the nine months ended September 30, 2003, revenue was $21,563,000 compared with $14,910,000 in the comparable nine-month period of the prior year, a
13
45% increase. The revenue growth was driven by the increase in the Company’s core revenue components of software license fees and maintenance and services revenue. Core revenue increased 42% to $6,896,000 for the third quarter of 2003 from $4,859,000 for the same period of 2002. For the nine months ended September 30, 2003, core revenue increased 53% to $19,925,000 from $12,994,000 for the nine months ended September 30, 2002. For the nine months ended September 30, 2003, revenue from sales to Toshiba Medical Systems Corporation (“Toshiba”) totaled $9,777,000, or 45% of 2003 total revenue, compared with $5,486,000, or 37% of 2002 total revenue for the nine months ended September 30, 2002.
The $1,236,000 increase in software license fee revenue for the quarter and the $4,921,000 increase for the year-to-date period resulted from an increase in Vitrea® 2, Vitrea 2 options and increased sales to Toshiba. Revenue from Vitrea 2 increased from $5,634,000 for the nine months ended September 30, 2002 to $7,491,000 for the nine months ended September 30, 2003 due to an increase in the number of software licenses shipped. For the nine months ended September 30, 2003, the Company generated 65% revenue growth from the sale of Vitrea 2 options, including VScore™, CT Colonography, Automated Vessel Measurements and CT Cardiac. The sale of Vitrea 2 options totaled $7,333,000 for the first nine months of 2003 compared with $4,452,000 in the first nine months of 2002. For the nine months ended September 30, 2003, software license fee revenue from sales to Toshiba totaled $7,803,000 compared with $4,647,000 for the nine months ended September 30, 2002.
Maintenance and services revenue increased 96% to $1,638,000 for the three months ended September 30, 2003 compared to $836,000 for the three months ended September 30, 2002. Maintenance and services revenue increased 75% to $4,689,000 for the nine months ended September 30, 2003 compared to $2,678,000 for the nine months ended September 30, 2002. Of the $2,011,000 increase for the nine months ended September 30, 2003 compared to 2002, $1,089,000 consisted of an increase in maintenance revenue and $819,000 was an increase in training revenue. For the three months ended September 30, 2003 compared to the same period in 2002, $545,000 of the $802,000 increase was an increase in maintenance revenue and $285,000 was an increase in training revenue. The increases for the three months ended September 30, 2003 were partially offset by a $38,000 decrease in installation revenue. The increases in maintenance revenue were due to the Company adding new customers to the installed base and collecting back maintenance from customers whose maintenance had lapsed. The number of Vitrea licenses shipped increased from approximately 800 as of September 30, 2002 to approximately 1,250 as of September 30, 2003. The increases in training revenue were due to an overall increase in the number of training sessions sold with the customers’ initial purchases of software. The increase in maintenance and services revenue for the nine months ended September 30, 2003 was partially due to an increase in revenue from engineering services rendered under product development agreements with Medtronic Surgical Navigation Technologies (“SNT”), E-Z-EM, Inc. and Toshiba. The Company generated $380,000 of such service revenue for the nine months ended September 30, 2003 from E-Z-EM, Inc. and SNT. For the first nine months of 2002, the Company had generated $320,000 for engineering services rendered to SNT and Toshiba.
Hardware revenue decreased 53% to $346,000 for the third quarter of 2003 from $734,000 in the third quarter of 2002. For the nine months ended September 30, 2003, hardware revenue decreased 15% to $1,638,000 from $1,917,000 for the nine months ended September 30, 2002. The decrease in hardware revenue was due to a decrease in the number of complete system sales and lower unit pricing for hardware platforms shipped in 2003.
Gross Margin
The gross margin percentage increased to 84% for both the three and nine months ended September 30, 2003,
14
respectively, from 80% and 78% for the three and nine months ended September 30, 2002, respectively. The increase in gross margin is partially attributable to the increase in software-only sales and sales of software options, which have higher margins. In addition, there was an increase in higher margin maintenance and services revenue. Software license revenue, which generates higher gross margins than hardware revenue, increased 48% for the nine months ended September 30, 2003 compared to the nine months ended September 30, 2002. Meanwhile, hardware revenue decreased 15% from the nine months ended September 30, 2002 as compared to the nine months ended September 30, 2003. The Company anticipates the overall gross margin percentage in future periods may be lower than the gross margin rates achieved in the first nine months of 2003, but this expectation will be affected by the amount of software-only revenue, the amount of lower-margin third-party software sales and the mix of revenue from maintenance and services and hardware.
Sales and marketing expenses increased to $2,930,000, or 40% of total revenue, for the three months ended September 30, 2003 from $2,201,000, or 39% of total revenue, for the three months ended September 30, 2002, a 33% increase. For the nine months ended September 30, 2003, sales and marketing expenses increased 48% to $8,737,000, or 41% of total revenue, from $5,893,000, or 40% of total revenue, for the nine months ended September 30, 2002. The increases were mostly due to increases in compensation costs as a result of additional personnel required to support recent growth and increased sales commissions as a result of increased revenue. Compensation costs increased $519,000 and $1,902,000 for the three and nine months ended September 30, 2003, respectively, compared to the same periods in 2002. Total sales and marketing personnel, including customer support personnel, increased from 47 at September 30, 2002 to 55 at September 30, 2003. Due to the increase in headcount, travel and entertainment expenses increased $104,000 and $237,000 for the three and nine months ended September 30, 2003, respectively, compared to the three and nine months ended September 30, 2002. Hiring costs were flat for the three months ended September 30, 2003 compared to the same period in 2002 and increased $113,000 for the nine months ended September 30, 2003 compared to the first nine months of 2002. There was also a $73,000 and $306,000 increase in expenses related to utilizing outside consultants to help sell and promote Vitrea 2 and Vitrea 2 options for the three and nine months ended September 30, 2003, respectively, compared to the same periods in 2002. The Company expects sales and marketing costs to increase in future periods as a result of the cost of additional sales and customer support personnel.
Research and development expenses increased 14% to $1,310,000, or 18% of total revenue, for the three months ended September 30, 2003, compared with $1,154,000, or 21% of total revenue, for the same period last year. For the nine month period ended September 30, 2003, research and development expenses increased 33% to $4,005,000, or 19% of total revenue, from $3,002,000, or 20% of total revenue, for the comparable period in the prior year. The expense increase was largely due to increased compensation costs resulting from additional personnel supporting the development of Vitrea 2. Compensation costs increased $34,000 and $568,000 for the three and nine months ended September 30, 2003, respectively, compared to the same periods in 2002. Total research and development personnel increased from 30 at September 30, 2002 to 36 at September 30, 2003. Due to the increase in personnel, hiring costs increased $21,000 and $35,000 for the three and nine months ended September 30, 2003, respectively, compared to the three and nine months of 2002. Due to more training and increased personnel, training costs increased $25,000 and $55,000 for the three and nine months ended September 30, 2003, respectively, compared to the same periods in 2002. There was a $160,000 decrease during the nine months ended September 30, 2003 in research and development expenses classified as cost of revenue due to less service being performed related to SNT product development
15
agreements. The Company anticipates that research and development costs will increase in future periods as the Company develops software tools for applications with large potential markets, such as cardiovascular disease, disease screening applications such as colon cancer, and surgical and therapy planning, but management expects these costs will decline as a percentage of total revenue.
General and administrative expenses increased to $967,000, or 13% of total revenue, for the three months ended September 30, 2003, from $737,000, or 13% of total revenue, for the three months ended September 30, 2002, a 31% increase. Of the $230,000 increase for the three months ended September 30, 2003 compared to September 30, 2002, $100,000 consisted of an increase in compensation costs related to additional personnel and $71,000 consisted of legal fees due to business development, patent work and SEC filings related to the registration statement covering the resale of shares from a private placement in June 2003. For the nine months ended September 30, 2003, general and administrative expenses increased 24% to $3,067,000, or 14% of total revenue, from $2,472,000, or 17% of total revenue, for the nine months ended September 30, 2002. The largest portion of the increase for the nine months ended September 30, 2003 compared to the nine months ended September 30, 2002 was a $341,000 increase in compensation costs related to additional personnel. Total general and administrative personnel increased from 15 at September 30, 2002 to 18 at September 30, 2003. For the nine months ended September 30, 2003, registration and filing fees increased $179,000, which includes a $100,000 NASDAQ National Market registration fee, as compared to the nine months ended September 30, 2002. This registration fee was paid for the first time in June 2003 when the Company qualified for listing on the National Market. In addition, legal fees increased $155,000 during the nine months ended September 30, 2003 due to business development, patent work and SEC filings. General and administrative expenses for the nine months ended September 30, 2002 includes $230,000 related to severance for the Company’s former chief executive officer. The Company believes that general and administrative expenses will increase in future periods due to increased infrastructure costs as the business grows, but management expects that these costs will remain unchanged or decrease from the current percentage of total revenue.
The increasing revenue from Vitrea 2 and add-on software options shipments, net of the increased expenses attributable to the development of the Company’s infrastructure and the development and promotion of the Vitrea 2 product, resulted in operating income of $895,000 and $2,199,000 for the three and nine months ended September 30, 2003, respectively, compared with operating income of $390,000 and $288,000 for the three and nine months ended September 30, 2002, respectively.
During the third quarter of 2003, the Company concluded that it is more likely than not that all of its net deferred tax assets will be realized and the Company reversed its valuation allowance for net deferred tax
16
assets, which resulted in the recording of a net tax benefit for the three months and nine months ended September 30, 2003. The reversal of the deferred tax assets valuation allowance is based upon the Company’s historical operating performance and management’s expectation that the Company will generate sufficient taxable income of approximately $25 million in future periods to allow it to realize its deferred tax assets resulting from the tax benefits associated with its net operating loss (“NOL”) carryforwards and a significant portion of its research and development tax credit carryforwards, as well as certain other tax benefits related to book and tax income timing differences. The reversal of the valuation allowance resulted in a $5,885,000 tax benefit in the statements of operations that was partially offset by a $45,000 and a $105,000 provision for state income taxes for the three and nine months ended September 30, 2003, respectively. The Company expects to reverse approximately $400,000 of the remaining valuation allowance of $545,000 in the fourth quarter of 2003. The Company’s effective tax rate for the third quarter of 2003, before the effect of the valuation allowance reversal, was approximately 5 percent, reflecting state income taxes and certain state minimum fees.
As of September 30, 2003, the Company had available NOL carryforwards of approximately $21.8 million and research and development tax credit carryforwards of approximately $978,000 expiring in varying amounts from 2003 through 2022.
As of September 30, 2003, the Company had $28,827,000 in cash and cash equivalents, working capital of $32,294,000, and no borrowings.
Cash flows provide by operations increased to $4.1 million in the first nine months of 2003 from $444,000 in the first nine months of 2002. In the nine-month period ended September 30, 2003, $11.3 million of the cash generated was from increases in net income, deferred revenue, non-cash expenses for depreciation and accrued expenses and other current liabilities. These increases were partially offset by an increase in accounts receivable and prepaid expenses and other current assets as well as a $5,885,000 increase in the deferred income tax benefit. In the nine month period ended September 30, 2002, $2.5 million of the cash generated was from increases in net income, deferred revenue and non-cash expenses related to depreciation. These increases were offset by a $2.2 million increase in accounts receivable.
Of the $1,716,000 and $1,436,000 increases in deferred revenue for the nine months ended September 30, 2003 and 2002, respectively, $1,231,000 and $561,000, respectively, were due to volume increases in Vitrea 2 sales and renewals of annual maintenance. The $1,404,000 increase and $2,179,000 increase in accounts receivable for the nine months ended September 30, 2003 and 2002, respectively, were due to revenue increases. The days sales outstanding on an annualized basis improved from 110 days at September 30, 2002 to 84 days at September 30, 2003. The increases in accounts payable and accrued expenses and other current liabilities for the nine months ended September 30, 2003 and 2002 were due to the timing of payments and the increasing level of expenses. The increase in prepaid expenses and other current assets for the nine months ended September 30, 2003 was due to a $188,000 increase in inventory, a $116,000 increase in prepaid insurance and a $100,000 increase in revenue in excess of billings related to service revenues recognized using the percentage of completion method.
The Company used $4,229,000 and $4,944,000 of cash for net investing activities in the nine months ended September 30, 2003 and 2002, respectively. Additions to property plant and equipment were $1,455,000 and $1,035,000 for the nine months ended September 30, 2003 and 2002, respectively. The purchases for both
17
periods were largely to upgrade computer equipment and to purchase computer equipment for new personnel. In addition, the Company purchased furniture and fixtures and leasehold improvements related to expansions of the Company’s offices in both periods. Management anticipates that the Company will continue to purchase property and equipment necessary in the normal course of business. The amount and timing of these purchases and the related cash outflows in future periods is difficult to predict and depends on a number of factors, including the hiring of employees and the rate of change of computer hardware. The Company used $6,203,000 and $5,932,000 to purchase marketable securities during the periods ended September 30, 2003 and 2002, respectively. The Company realized $3,429,000 and $2,023,000 of proceeds from maturities of marketable securities during the nine months ended September 30, 2003 and 2002, respectively. The marketable securities are invested in U.S. government obligations, U.S. government agency obligations, corporate commercial obligations and certificates of deposits.
Cash provided by financing activities totaled $20,852,000 and $2,789,000 for the nine months ended September 30, 2003 and 2002, respectively. Of the cash provided during the nine months ended September 30, 2003, $18,991,000 consisted of net proceeds, after deducting placement fees and other offering costs of $1,259,000, from the Company’s private placement of 1.5 million shares of common stock at $13.50 per share. A registration statement covering the resale of these shares was declared effective on September 29, 2003 by the Securities and Exchange Commission.
The remaining $1,861,000 and $2,789,000 of cash provided by financing activities in the 2003 and 2002 nine-month periods, respectively, were from the sale of common stock upon the exercise of options granted under stock option plans and the exercise of warrants. In December 2001, the Company announced its decision to exercise its right to redeem its outstanding redeemable, five-year common stock warrants issued in its December 1999 private placement. The warrant holders exercised all of the outstanding warrants in December 2001 and January 2002. The net cash proceeds from the January 2002 exercises were approximately $1,719,000. During the nine months ended September 30, 2003, the exercise of the broker warrants, issued in 1999 in connection with the private placement, generated $211,000 in cash.
The Company has never paid or declared any cash dividends and does not intend to pay dividends in the near future.
The following summarizes our contractual obligations due each period, including purchase commitments as of September 30, 2003, and the effect such obligations are expected to have on our liquidity and cash flow:
|
|
|
Payments Due By Year |
|
||||||||||
|
|
|
Remainder |
|
2004 |
|
2005 |
|
2006 |
|
||||
|
Operating leases |
|
$ |
108,000 |
|
$ |
434,000 |
|
$ |
255,000 |
|
$ |
19,000 |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Purchase commitment (1) |
|
$ |
420,000 |
|
$ |
1,715,000 |
|
$ |
1,890,000 |
|
$ |
1,575,000 |
|
(1) Assumes the R2 Technologies, Inc.’s lung nodule CAD software product will be available for sale beginning no earlier than the fourth quarter of 2003. (See Note 12 in the Notes to Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2002.)
If the Company’s operations progress as anticipated, of which there can be no assurance, management believes that its cash and cash equivalents on hand and generated from operations should be sufficient to satisfy its cash
18
requirements for at least the next 12 months. The timing of the Company’s future capital requirements, however, will depend on a number of factors, including the ability and willingness of physicians to use three-dimensional visualization and analysis software in clinical diagnosis, surgical planning, patient screening and other diagnosis and treatment protocols; the ability of the Company to successfully market its products; the ability of the Company to differentiate its volume rendering software from competing products employing surface rendering or other technologies; the ability of the Company to build and maintain an effective sales and distribution channel; the impact of competition in the medical visualization business; the ability of the Company to obtain any necessary regulatory approvals; and the ability of the Company to enhance existing products and develop new products on a timely basis. To the extent that the Company’s operations do not progress as anticipated, additional capital may be required. There can be no assurance that any required additional capital will be available on acceptable terms or at all, and the failure to obtain any such capital would have a material adverse effect on the Company’s business.
Substantially all of the Company’s foreign transactions are negotiated, invoiced and paid in U.S. dollars.
Certain Important Factors
This Form 10-Q contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and information that are based on management’s beliefs, as well as on assumptions made by, and upon information currently available to, management. When used in this Form 10-Q, the words “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” and “estimate” or similar expressions are intended to identify such forward-looking statements. However, this Form 10-Q also contains other forward-looking statements. Forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions, including, but not limited to, the following factors, which could cause the Company’s future results and shareholder values to differ materially from those expressed in any forward-looking statements made by or on behalf of the Company: the dependence on growth of the industry in which the Company operates, the extent to which the Company’s products continue to gain market acceptance, the need for and availability of additional capital, regulatory approvals, the potential for litigation regarding patent and other intellectual property rights, the introduction of competitive products by others, dependence on major customers, fluctuations in quarterly results, the progress of product development, the availability of third-party reimbursement, and the receipt and timing of regulatory approvals and other factors detailed from time to time in the Company’s filings with the Securities and Exchange Commission, including those set forth under the heading “Important Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2002.
19
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
For information regarding the Company’s exposure to certain market risks, see Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2002, which is hereby incorporated herein. There have been no significant changes in the financial instruments or market risk exposures from the amounts and descriptions disclosed therein.
ITEM 4. CONTROLS AND PROCEDURES
As of the end of the period covered by this report, an evaluation was performed by the Company’s management, including its principal executive officer and principal financial officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures. Based on that evaluation, the Company’s management, including its principal executive officer and principal financial officer, concluded that the Company’s disclosure controls and procedures were effective as of September 30, 2003.
There were no changes in the Company’s internal controls over financial reporting that occurred during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.
20
ITEM 1. LEGAL PROCEEDINGS
None.
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None.
None.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
|
(a) |
|
Exhibits. |
|
|
|
|
|
31.1 |
|
Certification of Chief Executive Officer Pursuant to Rules 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934 and Section 302 of the Sarbanes-Oxley Act of 2002. |
|
|
|
|
|
31.2 |
|
Certification of Chief Financial Officer Pursuant to Rules 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934 and Section 302 of the Sarbanes-Oxley Act of 2002. |
|
|
|
|
|
32.1 |
|
Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
|
|
|
|
32.2 |
|
Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
21
(b) Form 8-K.
During the quarter ended September 30, 2003, and during the period from September 30, 2003 until the date of this Quarterly Report, the Company furnished the following Current Reports on Form 8-K:
On July 28, 2003, the Company furnished the SEC with a Current Report on Form 8-K announcing the issuance of a press release on July 22, 2003 regarding Vital Images’ financial results for the three and six months ended June 30, 2003.
On October 21, 2003, the Company furnished the SEC with a Current Report on Form 8-K announcing the issuance of a press release on October 21, 2003 regarding Vital Images’ financial results for the three and nine months ended September 30, 2003.
22
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
VITAL IMAGES, INC. |
|
|
|
|
|
|
|
|
|
|
November 14, 2003 |
/s/ Gregory S. Furness |
|
|
|
Gregory S. Furness |
|
|
|
Chief Financial Officer and |
|
|
|
(Chief Accounting Officer) |
|
23